# US 2018/0021356 A1 · Treating Vitamin D Insufficiency and Deficiency With 25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021356 A1
- Document ID: US20180021356A1
- Status: Published application
- Kind: A1
- Application number: 15/722,757
- Filed: 2017-10-02
- Published: 2018-01-25
- Earliest claimed: 2006-02-03
- Assignees: Opko Renal, LLC
- Applicants: Opko Renal, LLC
- Inventors: Charles W. Bishop; Keith H. Crawford; Eric J. Messner
- Web page: https://patentgrep.com/patent/US20180021356A1

## CPC

- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 35/00: Antineoplastic agents
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.

## Claims

### Claim 1

A method of treating 25-hydroxyvitamin D insufficiency or deficiency in a patient comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, glycemic control agents, hypertension control agents, and antineoplastic agents.

### Claim 2 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more calcium salts.

### Claim 3 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more bisphosphonates.

### Claim 4 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with nicotinic acid.

### Claim 5 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with iron.

### Claim 6 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more phosphate binders.

### Claim 7 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more glycemic control agents.

### Claim 8 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more hypertension control agents.

### Claim 9 (depends on 1)

The method of claim 1, comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more antineoplastic agents.

### Claim 10

A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, cholecalciferol, ergocalciferol, active Vitamin D sterols, glycemic and hypertension control agents, and antineoplastic agents.

### Claim 11 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more calcium salts.

### Claim 12 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more bisphosphonates.

### Claim 13 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with nicotinic acid.

### Claim 14 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with iron.

### Claim 15 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more phosphate binders.

### Claim 16 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more glycemic control agents.

### Claim 17 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more hypertension control agents.

### Claim 18 (depends on 10)

The sustained release oral dosage formulation of claim 10, comprising 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more antineoplastic agents.

### Claim 19

A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 dispersed within a matrix and encased with a coating material.

### Claim 20 (depends on 19)

The sustained release oral dosage formulation of claim 19, having a melting point which is higher than body temperature but lower than the melting temperature of the coating material.

### Claim 21 (depends on 19)

The sustained release oral dosage formulation of claim 19, wherein the matrix comprises a lipid.

### Claim 22 (depends on 21)

The sustained release oral dosage formulation of claim 21, wherein the lipid comprises one or more glycerides, fatty acids, fatty alcohols, fatty acid esters, or combinations thereof.

### Claim 23 (depends on 22)

The sustained release oral dosage formulation of claim 22, wherein the lipid comprises one or more glycerides.

### Claim 24 (depends on 22)

The sustained release oral dosage formulation of claim 22, wherein the lipid comprises one or more fatty acids.

### Claim 25 (depends on 22)

The sustained release oral dosage formulation of claim 22, wherein the lipid comprises one or more fatty alcohols.

### Claim 26 (depends on 22)

The sustained release oral dosage formulation of claim 22, wherein the lipid comprises one or more fatty acid esters.

### Claim 27

A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 dispersed within a matrix and comprising a permeable overcoating.

### Claim 28 (depends on 27)

The sustained release oral dosage formulation of claim 27, wherein the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is released by diffusion.

### Claim 29 (depends on 27)

The sustained release oral dosage formulation of claim 27, wherein the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is released by disintegration of the matrix.

### Claim 30 (depends on 27)

The sustained release oral dosage formulation of claim 27, wherein the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is released by a combination of diffusion and disintegration of the matrix.

### Claim 31

A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 dispersed within a matrix which is solid at body temperature.

### Claim at position 32

-51. (canceled)

### Claim 52

A controlled release oral formulation comprising 25-hydroxyvitamin D3 and a pharmaceutical-grade matrix excipient.

### Claim 53

A controlled release formulation comprising 25-hydroxyvitamin D3 dispersed within a matrix wherein the matrix comprises a mixture of rate controlling constituents and excipients.

### Claim 54 (depends on 53)

The formulation according to claim 53, encased with a coating material.

### Claim 55 (depends on 53)

The formulation according to claim 53, wherein the rate controlling constituents are lipophilic.

### Claim 56 (depends on 55)

The formulation according to claim 55, encased with a coating material.

### Claim 57 (depends on 53)

The formulation according to claim 53 wherein the rate controlling constituent comprises a poly(meth)acrylate polymer.

### Claim 58 (depends on 57)

The formulation according to claim 57, encased with a coating material.

### Claim 59

A capsule comprising 25-hydroxyvitamin D3 and a controlled release excipient.

### Claim 60

A pharmaceutical composition comprising 25-hydroxyvitamin D3 and a controlled release delivery system.
